Yes


Antibody drugs are fast to develop and reasonably likely to work but inefficient in terms of manufacturing,” says Skovronsky at Lilly. He says companies, nonprofits, and the government are discussing how to share manufacturing plants. “If it turns out our antibody doesn’t work and someone else’s does, probably we would offer capacity for them. And the opposite would be true,” he says. “No one is looking at this as a moneymaking commercial business. It’s just how quickly can we help.”